JBI-802 Shows Early Platelet Control in MPNs

Company Jubilant Therapeutics Event Type First Clinical Disclosure (Phase I/II) Modality Oral Dual Small-Molecule Inhibitor (LSD1 and HDAC6) Asset JBI-802 Target LSD1 and HDAC6 Disease Area Essential Thrombocythemia, Polycythemia Vera, Myelofibrosis, MDS/MPN With Thrombocytosis Summary In the first clinical disclosure from an ongoing Phase I/II…